Published in Gene Therapy Weekly, December 27th, 2001
The patent broadly covers a commercial-scale process for generating antigen-specific T cells that may be used for therapeutic benefit or for a variety of drug development initiatives. Targeted Genetics' portfolio of cell therapy assets, including more than 70 patents and patent applications, are the foundation upon which CellExSys was established.
"This patent strengthens and extends the protection of our proprietary Rapid Expansion Method...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.